Yi-Ping Wang1, Dong-Xin Tang2. 1. Department of Gastroenterology, Changzheng Hospital, Second Military Medical University Shanghai 200003, China. 2. Department of Oncology, The First Affiliated Hospital of Guiyang College of TCM Guiyang 550001, China.
Abstract
OBJECTIVE: To investigate the expression of Yes-associated protein (YAP) in liver cancer and its correlation with clinicopathological features and prognosis of liver cancer patients. METHODS: A total of 95 patients receiving surgery due to liver cancer were recruited. RESULTS: In 95 liver cancers, YAP expression was significantly higher than that in adjacent normal tissues. In addition, of liver cancers, 14.7% was negative for YAP (14/95), 29.5% (28/95) weakly positive, 21.1% (20/95) positive and 34.7% (33/95) strong positive, and low expression and high expression were observed in 44.2% (42/95) and 55.8% (53/95) of liver cancers, respectively. Of adjacent normal tissues, 13.7% (13/95) were negative or weakly positive for YAP. The mean survival time of patients with high YAP expression was significantly longer than that of patients with low YAP expression (Log-rank = 9.206, P < 0.01). Univariate analysis showed portal vein thrombosis (P < 0.01), metastasis (P < 0.01), American Joint Committee on Cancer Staging (AJCC) stage (P < 0.01), alpha fetoprotein (AFP) (P < 0.01) and high YAP expression (P < 0.01) were factors affecting the overall survival of liver cancer patients. However, multivariate analysis showed metastasis (P < 0.01) and high YAP expression (P < 0.01) were independent risk factors of overall survival of liver cancer patients. CONCLUSION: YAP expression increases significantly in liver cancer and it may be involved in the occurrence and development of liver cancer. YAP expression is an independent risk factor affecting the overall survival of liver cancer patients.
OBJECTIVE: To investigate the expression of Yes-associated protein (YAP) in liver cancer and its correlation with clinicopathological features and prognosis of liver cancerpatients. METHODS: A total of 95 patients receiving surgery due to liver cancer were recruited. RESULTS: In 95 liver cancers, YAP expression was significantly higher than that in adjacent normal tissues. In addition, of liver cancers, 14.7% was negative for YAP (14/95), 29.5% (28/95) weakly positive, 21.1% (20/95) positive and 34.7% (33/95) strong positive, and low expression and high expression were observed in 44.2% (42/95) and 55.8% (53/95) of liver cancers, respectively. Of adjacent normal tissues, 13.7% (13/95) were negative or weakly positive for YAP. The mean survival time of patients with high YAP expression was significantly longer than that of patients with low YAP expression (Log-rank = 9.206, P < 0.01). Univariate analysis showed portal vein thrombosis (P < 0.01), metastasis (P < 0.01), American Joint Committee on Cancer Staging (AJCC) stage (P < 0.01), alpha fetoprotein (AFP) (P < 0.01) and high YAP expression (P < 0.01) were factors affecting the overall survival of liver cancerpatients. However, multivariate analysis showed metastasis (P < 0.01) and high YAP expression (P < 0.01) were independent risk factors of overall survival of liver cancerpatients. CONCLUSION:YAP expression increases significantly in liver cancer and it may be involved in the occurrence and development of liver cancer. YAP expression is an independent risk factor affecting the overall survival of liver cancerpatients.
Authors: Andrea Perra; Marta Anna Kowalik; Elena Ghiso; Giovanna Maria Ledda-Columbano; Luca Di Tommaso; Maria Maddalena Angioni; Carlotta Raschioni; Elena Testore; Massimo Roncalli; Silvia Giordano; Amedeo Columbano Journal: J Hepatol Date: 2014-07-07 Impact factor: 25.083
Authors: Masahiro Tsujiura; Virginia Mazack; Marius Sudol; Hanna G Kaspar; John Nash; David J Carey; Radhika Gogoi Journal: PLoS One Date: 2014-06-27 Impact factor: 3.240
Authors: Sarah A Smith; Richard B Sessions; Deborah K Shoemark; Christopher Williams; Reza Ebrahimighaei; Madeleine C McNeill; Matthew P Crump; Tristan R McKay; Gemma Harris; Andrew C Newby; Mark Bond Journal: J Med Chem Date: 2019-01-31 Impact factor: 7.446